GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01249131
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01243892
A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01240226
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01229215
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01226277
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01225393
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01209130
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01209143
A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01207323
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Uni of Colorado Cancer Center; Anschutz Cancer Pavilion, Aurora, Colorado, United States
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT01201915
© Copyright 2024. All Rights Reserved by MedPath